NCT06807151

Brief Summary

This study aimed to evaluate the clinical value of plasma diquat concentration in guiding personalized extracorporeal treatment regimens for patients with acute diquat poisoning.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
163

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2023

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

January 29, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 4, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 12, 2025

Completed
Last Updated

April 22, 2025

Status Verified

April 1, 2025

Enrollment Period

1.5 years

First QC Date

January 29, 2025

Last Update Submit

April 17, 2025

Conditions

Diquat PoisoningBlood Purification

Keywords

diquatpoisoningextracorporeal treatmenthemoperfusioncontinuous kidney replacement treatment

Outcome Measures

Primary Outcomes (2)

  • 28-day survival

    The primary outcome measure included 28-day survival (survived or died).

    28 days from the index date

  • Time from exposure to death

    The primary outcome measure included time from exposure to death.

    28 days from the index date

Interventions

Extracorporeal TreatmentPROCEDURE

Extracorporeal treatments in our study included hemoperfusion and continuous veno-venous hemodiafiltration.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with acute diquat poisoning

You may qualify if:

  • history of oral exposure to diquat solution reported by patient or proxy;
  • a specimen for the plasma diquat concentration collected immediately upon admission;
  • documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.
  • Patients were excluded if:
  • they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
  • diquat was not detected in specimens, or plasma concentration data were unavailable;
  • patients with an exposure time (time from exposure to presentation) longer than 48 hours;
  • patients had ECTR prior to ED presentation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Serum, Plasma

MeSH Terms

Conditions

Poisoning

Interventions

Extracorporeal Membrane Oxygenation

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Respiratory TherapyTherapeuticsExtracorporeal CirculationSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, Chief Physician

Study Record Dates

First Submitted

January 29, 2025

First Posted

February 4, 2025

Study Start

February 1, 2022

Primary Completion

July 31, 2023

Study Completion

April 12, 2025

Last Updated

April 22, 2025

Record last verified: 2025-04

Locations

CN(1)